| Followers | 131 |
| Posts | 15004 |
| Boards Moderated | 0 |
| Alias Born | 06/04/2018 |
Friday, October 30, 2020 5:15:34 PM
News; $CASI Top Penny Stocks To Buy Now According To Analysts; 1 Up 250%+ In 2020
Do Analysts Think These Are Penny Stocks To Buy Now? This has been one of the roughest weeks for penny stocks and blue chip stocks alike. The sheer force of this October sell-off is something we haven’t seen the likes of since March. In fact, if you look at the S&P 50...
Read the whole news CASI - Top Penny Stocks To Buy Now According To Analysts; 1 Up 250%+ In 2020
Do Analysts Think These Are Penny Stocks To Buy Now? This has been one of the roughest weeks for penny stocks and blue chip stocks alike. The sheer force of this October sell-off is something we haven’t seen the likes of since March. In fact, if you look at the S&P 50...
Read the whole news CASI - Top Penny Stocks To Buy Now According To Analysts; 1 Up 250%+ In 2020
@whytestocks
Recent CASI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/03/2026 02:00:21 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/26/2026 01:09:32 PM
- CASI Pharmaceuticals to be delisted from Nasdaq effective Wednesday • IH Market News • 02/25/2026 03:29:39 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 02:10:17 PM
- CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel • ACCESS Newswire • 02/25/2026 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2026 02:00:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/19/2026 02:00:37 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/10/2026 02:00:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2026 02:00:14 PM
- CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) • ACCESS Newswire • 01/15/2026 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/13/2026 02:00:07 PM
- CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia • ACCESS Newswire • 01/12/2026 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2025 09:15:44 PM
- CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements • ACCESS Newswire • 12/23/2025 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2025 02:15:09 PM
- CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing • ACCESS Newswire • 12/11/2025 02:00:00 PM
- CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting • ACCESS Newswire • 12/08/2025 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/19/2025 02:15:18 PM
- CASI Pharmaceuticals Announces Changes in Board Governance • ACCESS Newswire • 11/19/2025 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/14/2025 09:30:14 PM
